Ipamorelin research: published evidence reviewed
A clean pharmacology story in animals and early human work — with a smaller long-term outcome record than the marketing usually suggests.
TL;DR
- Ipamorelin is a growth hormone-releasing peptide (GHRP) that, in animal studies, triggered a pulse of growth hormone with little effect on cortisol or prolactin.
- The published research is mostly animal and early-phase human pharmacology, not long-term outcome trials.
- Selectivity is its defining feature in the literature — in animal studies, clean stimulation of growth hormone, less collateral signaling.
What it is
Ipamorelin is a synthetic five-amino-acid peptide. It belongs to a class called growth hormone-releasing peptides (in plain English: small molecules that nudge the pituitary to release growth hormone). It was developed in the 1990s, and the first published pharmacology study described it as a more selective option than earlier GHRPs (Raun et al., European Journal of Endocrinology, 1998).
How it works
Picture the pituitary gland as a faucet for growth hormone. Earlier peptides in this class turned the faucet on, but they also splashed cortisol and prolactin out. In animal studies, ipamorelin opened just the growth hormone tap.
It binds to the ghrelin receptor (also called the growth hormone secretagogue receptor) on the pituitary. That binding triggers a pulse of growth hormone release. Animal studies showed minimal change in cortisol or prolactin, even at high doses (Raun et al., 1998).
Who asks about it
People usually arrive at ipamorelin after reading about growth hormone peptides for sleep, body composition, or recovery. The honest follow-up is: what does the research actually show, and where does it stop? That is what this post answers.
What the research says
The early pharmacology work, in rats and pigs, showed growth hormone release without a cortisol rise (Raun et al., 1998). A later trial tested ipamorelin for bowel recovery after surgery; it was well tolerated but did not outperform placebo (Beck et al., International Journal of Colorectal Disease, 2014). What the literature does not yet contain is large, long-term outcome studies of ipamorelin in healthy adults, for aging or body composition. The selectivity story is well-described. The decade-long outcome story is not.
Regulatory status and safety
Ipamorelin is not FDA-approved. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. Few side effects were reported in the early human studies, but long-term safety data are lacking.
The Halftime POV
The selectivity case for ipamorelin is real. The long-term human evidence is not yet at the level the marketing language sometimes suggests. We treat both at once: a clean mechanism story, and a research base that is still filling in.
Related reading:
- Ipamorelin: what this GHRP peptide is
- Ipamorelin and selectivity: what the research shows
- CJC-1295 and ipamorelin: the research on the pair
FAQ
Q: What has ipamorelin been studied for? A: Ipamorelin has been studied as a growth hormone secretagogue. Animal and early human work found that it triggers a pulse of growth hormone release; in animal studies, it had little effect on cortisol or prolactin. The selectivity is what set it apart from earlier GHRPs.
Q: Is ipamorelin FDA-approved? A: No. Ipamorelin is not FDA-approved as a finished drug product. Compounded ipamorelin is not FDA-approved. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list.
Q: What are the limits of the ipamorelin evidence base? A: Most of the published work is small early-phase pharmacology studies and animal research. Large, long-term outcome studies in healthy adults are lacking.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 2014.
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What has ipamorelin been studied for?
Ipamorelin has been studied as a growth hormone secretagogue. Animal and early human work found that it triggers a pulse of growth hormone release; in animal studies, it had little effect on cortisol or prolactin. The selectivity is what set it apart from earlier GHRPs.
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved as a finished drug product. Compounded ipamorelin is not FDA-approved. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list.
What are the limits of the ipamorelin evidence base?
Most of the published work is small early-phase pharmacology studies and animal research. Large, long-term outcome studies in healthy adults are lacking.
